Clinical Pharmacogenetics

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 179-195

  Flockhart, David A ^a   Bertilsson, Leif ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849143420     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50053-5     Document Type: Chapter

References (95)

1. Committee on Quality of Health Care in America. To err is human: Building a safer health system 1999, National Academy Press, Washington, DC. K. LT, C. JM, D. MS (Eds.).
2. Nebert DW. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 1997, 7:160-162.
3. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA. The hydrox-ylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995, 57:159-163.
4. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical sig-nificance of the cytochrome P450 2C19 polymorphism. Clin Pharmacokinet 2002, 41:642-654.
5. Furuta T, Ohashi K, Kamata T, Takashiima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998, 129:2158-2164.
6. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992, 2:1632-1652.
7. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999, 65:1631.
8. Kalow W, Bertilsson L. Interethnic factors affecting drug metabolism. Adv Drug Res 1994, 25:371-381.
9. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:1706-1708.
10. Schinkel AH, Wagenaar E, Mol CAM, van Deemter L. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97:526-530.
11. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Telligen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 1996, 88:424-435.
12. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2:181-190.
13. Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2:718.
14. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 1979, 16:69-76.
15. Eichelbaum M, Bertilsson L, Säwe J, Zekorn C. Poly-morphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 1982, 31:435-440.
16. Eichelbaum M, Gross AS The genetic polymor-phism of debrisoquine/sparteine metabolism: Clinical aspects. Pharmacogenetics of drug metabolism 1992, 662-669. Pergamon Press, New York. K. W (Ed.).
17. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1994, 55:648. erratum in.
18. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992, 51:913-958. erratum in.
19. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mepheny-toin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985, 38:1027-1030.
20. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: Comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991, 32:25-31.
21. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C. Chromosoaml assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987, 23:552-561.
22. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988, 331:1-53.
23. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991, 48:491-502.
24. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification [see comments]. Lancet 1990, 336:2517-2524.
25. Heim M, Meyer UA. Evolution of a highly polymor-phic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992, 14:994-999.
26. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996, 6:584-586.
27. Dahl M-L, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxy-lation in a Swedish population. Clin Pharmacol Ther. 1992, 51:718.
28. Bertilsson L, Dahl M-L, Dalén P, Al-Sjurbaji A. Molec-ular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002, 54:183-187.
29. Wang S-L, Huang J-D, Lai M-D, Liu B-H, Lai M-L. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993, 53:184-186.
30. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese chromosome P4502D locus: Characteriza-tion of variant CYP2D6 genes present in subjects with diminished capacity for debrisoqui. Mol Pharmacol 1994, 46:625-648.
31. Masimirembwa C, Hasler JA, Bertilsson L, Johansson I, Ekberg O, Ingelman-Sundberg M. Phenotype genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correla. Eur J Clin Pharmacol 1996, 51:648.
32. Wennerholm A, Johansson I, Massele AY, Jande M, Alm C, Aden-Abdi Y, Dahl M-L, Ingelman-Sundberg M, Bertilsson L, Gustafsson LL. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999, 9:388-397.
33. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M. Analysis of the CYP2D6 muta-tions and their consequences for enzyme function in a West African population. Pharmacogenetics 1999, 9:402-408.
34. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distri-bution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and mul-tiduplicated functional CYP2D6 allele. J Pharmacol Exp Ther 1996, 278:504-507.
35. Wennerholm A, Dandara C, Sayi J, Svennson J-O, Aden Abdi Y, Ingeman-Sundberg M, et al. The African-specific CYP2D6 and 17 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002, 71:455-458.
36. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydrox-ylation as demonstrated by phenotyping and geno-typing of Ethiopians living in Et. Pharmacogenetics 2002, 12:442-446.
37. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debriso-quine: A case report with implication for treatment with nortryptyline and other tricyclic antidepressants. Ther Drug Monitor 1985, 7:943-950.
38. Bertilsson L, Dahl M-L, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for ratio-nal megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993, 341:63.
39. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993, 90:529-532.
40. Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl M-L, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultra-rapid metabolism of debrisoquine. Pharmacogenetics 1999, 9:49-58.
41. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995, 274:193-201.
42. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997, 60:12-17.
43. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its reper-cussion on the oxidative phenotype in a white popu-lation. Clin Pharmacol Ther 1995, 57:111-122.
44. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl M-L. Cytochrome P450 2D6 geno-type and steady state plasma levels of risperi-done and 9-hydroxyrisperidone. Psychopharmacol-ogy 1999, 147:410-418.
45. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997, 7:452-459.
46. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: Ultra-rapid metabolism of antidepressants as a cause of non respons. Eur J Clin Pharmacol 1904, 59:117-122.
47. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz H-U, Sjöqvist F. Nortryptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980, 27:707-714.
48. Mellström B, Bertilsson L, Säwe J, Schulz H-U, Sjöqvist F. E-and Z-10-hydroxylation of nortryptyline: Relationship to polymorphic debrisoquine hydroxyla-tion. Clin Pharmacol Ther 1991, 30:715-723.
49. Dalén P, Dahl M-L, Ruiz MLB, Nordin J, Eng R, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 012 3 and 13 functional CYPD6 genes. Clin Pharmacol Ther 1998, 63:441-446.
50. Dahl M-L, Bertilsson L, Nordin C. Steady state plasma levels of nortryptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype. Psychopharma-cology 1996, 123:77-88.
51. Yue Q-Y, Zhong Z-H, Tybring G, Dalén P, Dahl M-L, Bertilsson L, Sjöqvist F. Pharmacokinetics of nortripty-line and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998, 64:375-383.
52. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortripty. J Clin Psychopharma-col 2000, 20:478-480.
53. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propanolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989, 45:63.
54. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996, 24:11825-11829.
55. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995, 57:657-660.
56. McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabo-lizers of debrisoquin. Clin Pharmacol Ther 1985, 38:516-520.
57. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Racial differences in drug response: Altered sensitivity to and clearance of propanolol in men of Chinese descent as compared with American whites. N Engl J Med 1989, 320:284-295.
58. Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine morphine in extensive and poor metabolizers of sparteine: Pharma-cokinetics analgesic effect and side effects. Eur J Clin Pharmacol 1996, 51:265-269.
59. Caraco Y, Sheller J, Wood AJ. Impact of ethnic ori-gin and quinidine coadministration on codeine's dis-position and pharmacodynamic effects. J Pharmacol ExpTher 1999, 290:300-305.
60. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activ-ity. Clin Pharmacol Ther 1993, 53:187-191.
61. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharma-col Ther 1992, 51:803-807.
62. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, et al. Desipramine phar-macokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psy-chopharmacol 1997, 17:1673-1677.
63. Shin JG, Soukhova N, Flockhart DA. Effect of antipsy-chotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos 1999, 27:189-193.
64. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics [see comments]. J Clin Psychiatry 1996, 57(suppl 11):444-452.
65. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991, 148:315-319.
66. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharma-cogenetics 1999, 9:384-390.
67. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: Clinical impor-tance and molecular mechanisms. Pharmacogenetics 1996, 6:141-149.
68. Weinshilboum RM, Sladek SL. Mercaptopurine phara-macogenetics: Monogenic inheritance of erythrocyte thiopurine methyltranferease activity. Am J Hum Genet 1980, 32:72-79.
69. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for aza-thioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126:350-355.
70. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase phar-macogenetics: Human gene cloning and characteri-zation of a common polymorphism. DNA Cell Biol 1996, 15:518-524.
71. Aarbakke J, Janka-Schaub G, Elion GB. Thiopurine biology and pharmacology. Trends Pharmacol Sci 1997, 18:409-413.
72. Lennard L. Clinical implications of thiopurine methyltransferase -optimization of drug dosage and potential drug interactions. Ther Drug Monitor 1998, 20:565-570.
73. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997, 62:289-295.
74. van Aken J, Schmedders M, Feuerstein G, Kollek R. Prospects and limits of pharmacogenetics: The thio-purine methyltransferase (TPMT) experience. Am J Pharmacogenomics 1903, 3:413-422.
75. Baker DE. Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev Gastroenterol Disord 1903, 3:401-409.
76. McLeod HL, Yu J. Cancer pharmacogenomics: SNPs chips and the individual patient. Cancer Invest 1903, 21:278-287.
77. Agúndez JAG, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996, 6:284-291.
78. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (nat2) gene. Pharmacogenetics 1994, 4:1078-1084.
79. Lin HJ, Han CY, Lin BK, Hardy S. Slow acety-lator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians blacks Hispanics and whites: Application to metabolic epidemiology. Am J Hum Genet 1993, 52:12-25.
80. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978, 298:790-792.
81. Kosowsky BD, Taylor J, Lown B, Ritchie RF. Long-term use of procaine amide following acute myocardial infarction. Circulation 1973, 47:1204-1210.
82. Lee EJ, Zhao B, Seow-Choen F. Relationship between polymorphism of N-acetyltransferase gene and sus-ceptibility to colorectal carcinoma in a Chinese pop-ulation. Pharmacogenetics 1998, 8:513-517.
83. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smok-ing N acetyltransferase 2 genetic polymorphisms and breast cancer risk. JAMA 1996, 276:651-662.
84. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Muta-tions in the gene encoding for the b2-adrenergic recep-tor in normal and asthmatic subjects. Am J Respir Cell Mol Bio 1993, 8:608-614.
85. 2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997, 156:17-30.
86. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999, 65:3-7.
87. 2-Adrenergic receptor haplotypes in mild moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998, 158:527-531.
88. Preuss CV, Wood TC, Szumlanski CL, Raftogianis RB, Otterness DM, Girard B, et al. Human histamine N-methyltransferase pharmacogenetics: Common genetic polymorphisms that alter activity. Mol Pharmacol 1998, 53:60-73.
89. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998, 32:149-155.
90. Abernethy DR, Babaoglu MO. Polymorphic variant of endothelial nitric oxide synthase (eNOS) markedly impairs endothelium-dependent vascular relaxation [abstract]. Clin Pharmacol Ther 2000, 67:141.
91. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor recep-tor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:150-157.
92. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 1989, 17:630-640.
93. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S) -warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4:423-428.
94. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 1902, 287:125-134.
95. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:827-834.